Tamil NaduNVX-CoV2373 DCGI approval for Novavax vaccine for children

NVX-CoV2373 DCGI approval for Novavax vaccine for children

Novavax has announced that it has approved the emergency use of the COVID-19 vaccine for children aged 12-18 in India.

The Drugs Controller General of India (DCGI) has approved the emergency use of the Novavax Covid-19 vaccine to further strengthen the war against corona in India.

DeltaCron, a new variant of the corona virus, has begun to spread in India. With 568 cases reported in 7 states, including Maharashtra-Delhi, the emergency use of the Novavax Covid-19 vaccine has been approved as a reassuring message to the people.

The Novavax vaccine is also known as NVX-CoV2373. In India, the vaccine was developed by the Serum Institute of India in Pune and launched under the brand name Novavax. This is the first approved protein based vaccine for use in India at this age.

DCGI approval for emergency use

The Drug Control Agency of India (DCGI) has approved the emergency use of the Novavax vaccine to prevent SAV-19 infection caused by the SARS-CoV-2 virus in 12-year-olds and older. DCGI on December 28 approved the emergency use of ‘Novavax’ for 18-year-olds and older. Earlier in December, the World Health Organization (WHO) approved the emergency use of Novavax.

Stanley C. Erk, President and CEO of Novavax, said ‘We are proud to be the first to receive this vaccine for children. Our data suggest that the efficacy and safety of this vaccine will provide alternative protein based vaccine protection for 12 year olds and over in India.

Adar Poonavalla, CEO, Serum Institute of India, said, “Novovax approval for children 12 years of age and older in India is an important step in strengthening our immunization efforts in India and low- and middle-income countries.

He added that we are proud to provide the protein based Covid-19 vaccine to our country’s youth with protection against infection.

Related Stories